NY-CPV
2.4.2024 15:01:33 CEST | Business Wire | Press release
Cohen Private Ventures (CPV), the family office of Steven A. Cohen, is proud to officially unveil New York Golf Club (NYGC) and its four-player roster of PGA TOUR stars featuring Rickie Fowler, Xander Schauffele, Matt Fitzpatrick and New York-native Cameron Young ahead of the inaugural 2025 TGL presented by SoFi season.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240402326760/en/
New York Golf Club team roster: Cameron Young, Matt Fitzpatrick, Xander Schauffele, Rickie Fowler (Photo: Business Wire)
New York is synonymous with world class, and its golf scene is no exception. Steeped in the history of the sport, with some of the greatest and most iconic courses in the world, NYGC is ready to build upon its rich legacy of golf and redefine what it means to be a golf club representing a city known for its constant reinvention. NYGC is excited to represent the tri-state area in this innovative and accessible version of the sport.
“New Yorkers expect and deserve the best, and we couldn’t be more excited to have four of the best players in the world serve as an extension of the thriving golf and sporting culture of our city and region,” said Steve Cohen, owner of the NYGC and the New York Mets. “Rickie, Xander, Matt, and Cameron’s unwavering dedication to the sport, successful track records, and passion for winning is undisputable, and we look forward to watching them compete on golf’s newest stage.”
TEAM NAME & LOGO
New York City is the greatest city in the world, and NYGC embraces the privilege and responsibility that comes with representing the five boroughs and surrounding communities. NYGC will build upon our world-class golfing and sports heritage to deliver a team New York fans can be proud of.
NYGC’s logo is inspired by New York’s state bird, the Eastern Bluebird. These birds are commonly found where forests meet fields, and particularly on golf courses. Our design features a dynamic swinging club crafted into the form of a wing with four grooves, one for each of our players. The circle pays homage to the circles on our scorecards and the iconic NYC Subway circle.
MEET THE PLAYERS
Fowler is one of the most popular players on the PGA TOUR. Since turning professional in 2009, he has recorded 10 professional wins, including the 2015 PLAYERS Championship. His most recent title came at the 2023 Rocket Mortgage Classic in July. Fowler brings a wealth of team golf experience as a veteran of five U.S. Ryder Cup teams, three U.S. Presidents Cup teams, one World Cup, Walker Cup and Palmer Cup teams from his time as an amateur player. He also represented the U.S. in the 2016 Olympic Games.
“I am thrilled to be joining New York Golf Club for the inaugural TGL season,” said Fowler. “It is an incredible opportunity to represent one of the greatest cities in the world, and I look forward to competing in 2025.”
Schauffele, currently No. 5 in the Official World Golf Ranking, has been a top-10 player in the world for the better part of the last five years and regularly placing in the Top 10 of major championships. Since turning professional in 2015, he has recorded seven PGA TOUR titles, two DP World Tour wins and an Olympic Gold Medal in Tokyo. He was named the PGA TOUR Rookie of the Year in 2016-2017 and represented the U.S. in two Presidents Cup teams and two Ryder Cup teams.
“I’ve built my career on a foundation of hard work, grit, and determination, which couldn’t better reflect the people of New York City,” said Schauffele. “It’s a true honor to both grow the game and represent this incredible city.”
Fitzpatrick became England’s first major champion since 2016 when he won the 2022 U.S. Open at The Country Club in Brookline, Massachusetts, joining Jack Nicklaus as the only players to have won a U.S. Open and U.S. Amateur at the same venue. Since turning professional in 2014, Fitzpatrick has recorded two PGA TOUR titles and eight international victories, and represented England on three European Ryder Cup teams. His most recent PGA TOUR victory came at the RBC Heritage in April 2023.
“Working with the team at Cohen Private Ventures on the launch of New York Golf Club has been an incredible experience,” said Fitzpatrick. “New York is one of the greatest cities in the world, and I could not be more excited to continue to deepen my connections there.”
The New York-native Young is quickly becoming a fan favorite on the PGA TOUR. In 2022, Young earned Rookie of the Year honors when he became the seventh player since 1980 to collect five runner-up finishes in a season, including a second-place finish at The Open Championship and tying for third at the PGA Championship. He made his debut on the Presidents Cup team in 2022. Cameron’s father David Young, recently retired after over 20 years as Sleepy Hollow Country Club’s Head Golf Professional.
“Having grown up a New Yorker, first learning to play at Sleepy Hollow, the opportunity to represent New York Golf Club feels surreal,” said Young. “Alongside Rickie, Xander, and Matt, I am confident we are going to be a highly competitive team in the upcoming TGL season.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240402326760/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom